A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

The global dialysis equipment market is on a strong growth trajectory, with projected sales expected to increase from USD 11,126.0 million in 2024 to an impressive USD 17,780.9 million by 2034. This ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Renal fibrosis is one of the main pathological features of chronic kidney disease (CKD), and its treatment has been a hot research topic. Recent studies have shown that stem cell therapy can repair ...

Its growth is driven by the rising prevalence of kidney and urological disorders. The global market for nephrology and ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

There’s hope for patients living with end-stage kidney disease complications in the Ashanti Region and beyond, as a team of ...

Children with AAV and kidney disease face increased risks for long-term renal damage at 1 year, despite the majority achieving inactive renal disease by this time.

Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted Talphera's focus on ...

There are certain criteria for the diagnosis of acute renal failure. If you have one of the following three criteria in the course of 48 hours, this means that you have acute renal failure: If your ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...